From: Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial
Secondary Endpoint
Assumed Rate in CT-Guided SBRT Arm
Absolute Difference at 80% Power (n = 150 per arm)
Acute grade ≥ 2 GI toxicity
16.0%
8.3%
Late grade ≥ 2 GU toxicity
13.3%
12.8%
Late grade ≥ 2 GI toxicity
2.0%
7.5%